Advertisement

Topics

Prostate cancer: A new standard-of-care for advanced-stage disease

07:18 EDT 9 Aug 2017 | Nature Publishing

First-line, potent androgen blockade for patients with newly diagnosed, advanced-stage, castration-sensitive prostate cancer is confirmed as an effective strategy by data from the STAMPEDE and LATITUDE trials. Herein, we highlight the benefits, discuss caveats and consider the clinical care implications of these findings.

Original Article: Prostate cancer: A new standard-of-care for advanced-stage disease

NEXT ARTICLE

More From BioPortfolio on "Prostate cancer: A new standard-of-care for advanced-stage disease"

Quick Search
Advertisement
 

Searches Linking to this Story